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• Identify medications prescribed to manage NAS due to 
opioids and/or amphetamines
• Evaluate average daily medication wean rates 
• Assess length of stay (LOS) and length of treatment 
(LOT)
• Results of this study provide baseline descriptive 
statistics that may aid in evaluation of future NAS 
treatment plans or protocols at St. Cloud Hospital
• Many patients managed non-pharmacologically
• Most commonly prescribed medication for withdrawal 
was morphine 
• Clonidine was utilized as additive therapy in 
patients with higher NAS scores
• Patients who required dual therapy typically had a 
longer LOT and LOS
• Medication wean rates were inconsistent and lower 
than expected
• Calculating wean rates proved difficult 
• Assessment of medications for NAS was limited to 
inpatient use
• Other limitations include a lack of standardization for 
nurses to record NAS scores and a small study 
population
• IRB-approved, retrospective chart review of patients 
with an ICD-10 code for NAS from August 22, 2015 
to August 22, 2018
• Exclusion criteria:
• Unconfirmed NAS diagnosis
• NAS not pharmacologically managed
• Neonatal abstinence syndrome (NAS) is withdrawal 
from in utero exposure to opioids, amphetamines, 
benzodiazepines, selective serotonin reuptake inhibitors 
or nicotine1
• Pharmacological treatment for NAS includes morphine, 
methadone, phenobarbital, and clonidine2
• St. Cloud Hospital utilizes the Modified Finnegan Score 
to assess NAS but does not have a standardized 
protocol for managing this condition
70 Identified
30: No medications
6: Dx not confirmed
25 Morphine
2 Clonidine
7 Morphine + Clonidine
34 Included
Patient Characteristics 
Gestational Age (mean) 38 weeks,    
4 days
Birth weight (mean) 3.08 kg
Sex (female) 53%
Opioid withdrawal 21 patients
Amphetamine withdrawal 1 patient
Opioid and amphetamine withdrawal 12 patients
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